Completed PHASE1 INTERVENTIONAL 3-arm NCT04426708

A Clinical Study to Access the Pharmacokinetics of HMS5552 in Hepatic Impaired Subjects and Healthy Volunteers

An Open-Label, Paralleled Study of the Pharmacokinetics of HMS5552 Following a Single Oral Dose in Mild and Moderate Hepatic Impaired Subjects and Matched Healthy Volunteers

Sponsor: Hua Medicine Limited

Conditions Type 2 Diabetes Mellitus

Interventions HMS5552

Updated 6 times since 2020 Last updated: Nov 28, 2022 Started: Feb 18, 2019 Primary completion: Jul 3, 2020 Completion: Jul 3, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Type 2 Diabetes Mellitus, this trial is completed. The trial is conducted by Hua Medicine Limited and has accumulated 6 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Dec 2022 — Jul 2024 [monthly]

Completed PHASE1

Status: Unknown Status → Completed
Jul 2022 — Dec 2022 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jan 2021 — Jul 2022 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

Jul 2020 — Jan 2021 [monthly]

Recruiting PHASE1

First recorded

Feb 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hua Medicine Limited

Data source: Hua Medicine Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chengdu, China